IL1A and cancer: Conversely to HCV-infected patients with resolved HBV infection, non-HCV-infected patients with HBV reactivation during anti-cancer/immunosuppressive therapy or BMT had significantly higher IL-1α and -1β levels than did those without HBV reactivation (Fig. 5 and Supplementary Table S3).